TrialAmerican journal of epidemiology2026

Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up.

Ethan Ashby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.